中兽医医药杂志2025，Vol.44Issue(2)：78-84,7.DOI:10.13823/j.cnki.jtcvm.2025.015
不同中药方剂对鸡人工感染大肠杆菌病药效试验
Pharmacodynamic experiment of different traditional Chinese medicine prescriptions in preventing and treating chicken artificial infection of Escherichia coli
摘要
Abstract
In order to screen out the effective traditional Chinese medicine prescriptions for the prevention and treatment of chicken colibacillosis,oral gavage of Escherichia coli CVCC1558 strain was used to carry out the artificial pathogenesis of SPF chicken colibacillosis,and four kinds of formulas were selected as the experimental drugs,including Shengjiang San,Ganlu Xiaodu Dan,Yinqiao San and Dayuan Yin,for the clinical efficacy test.Six groups were set up in the experiment,in which group A was only given Shengjiang San,group B was given Shengjiang San and Ganlu Xiaodu Dan,group C was given Shengjiang San and Yinqiao San,group D was given Shengjiang San and Dayuan Yin,group E was the positive control group,and group F was the negative control group.The same feeding and management were conducted in all groups,and the experiment lasted for 9 consecutive days.The mental performance,fecal status,body temperature,weight gain,white blood cell count,pathological and anatomical changes of the experimental chickens were observed and determined.The results showed that all experimental chickens showed symptoms of depression and diarrhea after challenge,no sick chickens died,and the chicks in the negative control group were in normal spirit.In group A,B,C and D,the average proportion of mentally normal chickens was 71.1%,80.0%,76.7%and 83.3%,respectively,and the positive control group was 55.6%.The degree of diarrhea in each medication group was significantly lighter than that in the positive control group(P<0.05),and the scores of diarrhea degree in each medication group were 2.33±0.71,2.33±0.50,2.33±0.50,2.44±0.53,and 3.00 in the positive control.The average body temperature of each medication group was(41.90±0.30)℃,(41.72±0.25)℃,(41.89±0.30)℃and(41.95±0.30)℃,while it was(42.09±0.27)℃in the positive control group,and(41.84±0.25)℃in the negative control group,respectively,indicating that all drugs had heat clearing effect.On the sixth day after challenge,the weight gain rates of the medication groups were 35.00%,35.27%,35.56%and 40.48%,while it was 35.97%and 40.66%in the positive control group and the negative control group,respectively;on the 9th day after challenge,the weight gain rates of the medication groups were 45.71%,47.41%,46.59%,52.64%,while it was 47.89%and 51.33%in the positive control group and the negative control group,respectively.Hematological examination showed that the white blood cell counts of the medication groups were 78.30×109/L,69.10×109/L,71.00×109/L and 74.30×109/L,while it was 87.60×109/L and 57.00×109/L in the positive control group and the negative control group,respectively.The white blood cell counts of the medication groups were less than that of the positive control group and higher than that of the negative control group,indicating that the inflammation of the medication groups was lighter than that of the positive control group.At necropsy,all medication groups showed enteritis lesions,while in addition to enteritis lesions,some chickens in the positive control group also had pericarditis and perihepatic inflammation changes,the negative control group had no obvious lesions.According to the efficacy evaluation indexes,compared with the positive control group and the negative control group,the four medication groups showed better therapeutic effects.Considering that the weight gain rate is a very important indicator in animal husbandry,the combination of Shengjiang San and Dayuan Yin can be preferred for the prevention and treatment of chicken colibacillosis.关键词
鸡大肠杆菌病/升降散/达原饮/药效试验Key words
chicken Escherichia coli infection/Shengjiang San/Dayuan Yin/efficacy trial分类
畜牧业引用本文复制引用
赵增成,衣云鹏,林树乾,杨世发,殷斌,刘月月,黄中利,宋士凯,闫遵祥,张荣岭,王海挺..不同中药方剂对鸡人工感染大肠杆菌病药效试验[J].中兽医医药杂志,2025,44(2):78-84,7.基金项目
山东省乡村振兴科技创新提振行动计划(2023TZXD083) （2023TZXD083）
山东省科技型中小企业创新能力提升项目(2023TSGC0092) （2023TSGC0092）
